Waldencast (NASDAQ:WALD) Shares Gap Down to $5.52

Waldencast plc (NASDAQ:WALD) shares gapped down before the market opened on Tuesday . The stock had previously closed at $5.52, but opened at $5.23. Waldencast shares last traded at $5.31, with a volume of 5,359 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Telsey Advisory Group lowered their target price on shares of Waldencast from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Friday, March 22nd.

Waldencast Stock Performance

The company’s 50 day simple moving average is $6.57 and its 200-day simple moving average is $8.27.

Hedge Funds Weigh In On Waldencast

Institutional investors have recently made changes to their positions in the business. Dynamo Internacional Gestao DE Recursos LTDA. lifted its stake in shares of Waldencast by 4.6% in the 3rd quarter. Dynamo Internacional Gestao DE Recursos LTDA. now owns 15,332,933 shares of the company’s stock worth $144,436,000 after purchasing an additional 674,600 shares during the period. Barclays PLC increased its holdings in Waldencast by 75.3% in the 3rd quarter. Barclays PLC now owns 7,177 shares of the company’s stock worth $67,000 after acquiring an additional 3,084 shares in the last quarter. SG Americas Securities LLC increased its holdings in Waldencast by 23.2% in the 4th quarter. SG Americas Securities LLC now owns 19,705 shares of the company’s stock worth $216,000 after acquiring an additional 3,716 shares in the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in Waldencast in the 3rd quarter worth approximately $97,000. Finally, Bank of New York Mellon Corp increased its holdings in Waldencast by 73.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 86,409 shares of the company’s stock worth $814,000 after acquiring an additional 36,642 shares in the last quarter. Institutional investors own 41.97% of the company’s stock.

About Waldencast

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.